OBJECTIVES/HYPOTHESIS: To determine if elderly patients with oropharyngeal squamous cell carcinoma (OPSCC) are receiving less treatment and to evaluate the benefit of aggressive therapy in this population. STUDY DESIGN: Retrospective analysis of a large population database. METHODS: Patients in the Surveillance, Epidemiology, and End Results database with OPSCC diagnosed from 2004 to 2009 were included. The patients were categorized into age groups 45 to 54, 55 to 64, 65 to 74, 75 to 84, and 85 years and older, then further categorized by treatment status. Kaplan-Meier analysis of disease-specific survival (DSS) for late-stage (III and IV) OPSCC was performed for all age and treatment categories, followed by a multivariate cox regression of treatment status, tumor site, race, stage, and sex per age group. RESULTS: A total of 14,909 patients with OPSCC were identified. In our demographic data, we observed a significant increase in the number of patients who did not receive treatment (surgery, radiation, or combined therapy) after age 55. Kaplan-Meier analysis showed that age groups 65 to 74 and 75 to 84 had substantial benefits in DSS with surgery, radiation, or combined therapy. Multivariable analysis did not demonstrate any statistically significant difference in the hazard ratios for combined treatment among age groups 45 to 54, 55 to 64, 65 to 74, and 75 to 84. CONCLUSIONS: Proportionally fewer elderly patients with OPSCC are being treated than younger individuals. These patients can have significant benefits from aggressive treatments despite their older age as shown by our survival analysis. We recommend the use of objective measures to assess patient fitness to reduce the potential for undertreatment in the elderly population.
OBJECTIVES/HYPOTHESIS: To determine if elderly patients with oropharyngeal squamous cell carcinoma (OPSCC) are receiving less treatment and to evaluate the benefit of aggressive therapy in this population. STUDY DESIGN: Retrospective analysis of a large population database. METHODS:Patients in the Surveillance, Epidemiology, and End Results database with OPSCC diagnosed from 2004 to 2009 were included. The patients were categorized into age groups 45 to 54, 55 to 64, 65 to 74, 75 to 84, and 85 years and older, then further categorized by treatment status. Kaplan-Meier analysis of disease-specific survival (DSS) for late-stage (III and IV) OPSCC was performed for all age and treatment categories, followed by a multivariate cox regression of treatment status, tumor site, race, stage, and sex per age group. RESULTS: A total of 14,909 patients with OPSCC were identified. In our demographic data, we observed a significant increase in the number of patients who did not receive treatment (surgery, radiation, or combined therapy) after age 55. Kaplan-Meier analysis showed that age groups 65 to 74 and 75 to 84 had substantial benefits in DSS with surgery, radiation, or combined therapy. Multivariable analysis did not demonstrate any statistically significant difference in the hazard ratios for combined treatment among age groups 45 to 54, 55 to 64, 65 to 74, and 75 to 84. CONCLUSIONS: Proportionally fewer elderly patients with OPSCC are being treated than younger individuals. These patients can have significant benefits from aggressive treatments despite their older age as shown by our survival analysis. We recommend the use of objective measures to assess patient fitness to reduce the potential for undertreatment in the elderly population.
Authors: David Goldenberg; Heath Mackley; Wayne Koch; Darrin V Bann; Eric W Schaefer; Christopher S Hollenbeak Journal: Oral Oncol Date: 2014-08-19 Impact factor: 5.337
Authors: Sheela Hanasoge; Kelly R Magliocca; Jeffrey M Switchenko; Nabil F Saba; J Trad Wadsworth; Mark W El-Deiry; Dong M Shin; Fadlo Khuri; Jonathan J Beitler; Kristin A Higgins Journal: Head Neck Date: 2015-07-30 Impact factor: 3.147
Authors: Ronald Maggiore; Zachary S Zumsteg; Karlynn BrintzenhofeSzoc; Kelly M Trevino; Ajeet Gajra; Beatriz Korc-Grodzicki; Joel B Epstein; Stewart M Bond; Ira Parker; Julie A Kish; Barbara A Murphy; Noam A VanderWalde Journal: Int J Radiat Oncol Biol Phys Date: 2017-07-15 Impact factor: 7.038
Authors: Melina J Windon; Gypsyamber D'Souza; Farhoud Faraji; Tanya Troy; Wayne M Koch; Christine G Gourin; Ana P Kiess; Karen T Pitman; David W Eisele; Carole Fakhry Journal: Cancer Date: 2019-01-15 Impact factor: 6.860
Authors: Melina J Windon; Gypsyamber D'Souza; Eleni M Rettig; William H Westra; Annemieke van Zante; Steven J Wang; William R Ryan; Wojciech K Mydlarz; Patrick K Ha; Brett A Miles; Wayne Koch; Christine Gourin; David W Eisele; Carole Fakhry Journal: Cancer Date: 2018-04-30 Impact factor: 6.860
Authors: Thomas F Barrett; Angela L Mazul; Katelyn O Stepan; C Burton Wood; Randall C Paniello; Jose P Zevallos; Sean Massa; Ryan S Jackson; Nicole C Schmitt; Joseph Zenga; Stephen Y Kang; Patrik Pipkorn; Jason T Rich; Sidharth V Puram Journal: Oral Oncol Date: 2021-05-12 Impact factor: 5.972
Authors: Clark DuMontier; Kah Poh Loh; Paul A Bain; Rebecca A Silliman; Tammy Hshieh; Gregory A Abel; Benjamin Djulbegovic; Jane A Driver; William Dale Journal: J Clin Oncol Date: 2020-04-06 Impact factor: 50.717
Authors: Daniel R Dickstein; Marc Egerman; Erica Monrose; Achintya Varma; Umut Ozbek; Sonam Sharma; Jerry T Liu; Vishal Gupta; Marshall R Posner; Krzysztof Misiukiewicz; Brett A Miles; Eric Genden; Richard L Bakst Journal: Head Neck Date: 2020-12-08 Impact factor: 3.821